期刊的影响因子--文章列表

期刊文章列表
Yuyun Tang¹，Jinchao Gao¹，Tao Wang²，Qian Zhang¹，Antian Wang¹，Meng Huang¹，Renhe Yu¹，Hongzhuan Chen^1,3，Xiaoling Gao¹（Department of Pharmacology and Chemical Biology，Shanghai Universities Collaborative Innovation Center for Translational Medicine，Shanghai Jiao Tong University School of Medicine；Department of Geriatric Psychiatry，Shanghai Mental Health Center，Shanghai Jiao Tong University School of Medicine，Alzheimer's Disease and Related Disorder Center，Shanghai Jiao Tong University；Institute of Interdisciplinary Integrative Biomedical Research，Shuguang Hospital，Shanghai University of Traditional Chinese Medicine）.The effect of drug loading and multiple administration on the protein corona formation and brain delivery property of PEG-PLA nanoparticles[J].Acta Pharmaceutica Sinica B,2022,第4期 Mélanie Robert^1,2,3，Bastien Laperrousaz¹，Diana Piedrahita¹，Emilie-Fleur Gautier^3,4，Travis Nemkov^5,6，Florian Dupuy^4,7，Elie Nader^2,3，Virginie Salnot⁴，Patrick Mayeux^3,4，Angelo D’Alessandro^5,6，Catherine Lavazec^4,7，Philippe Joly^2,3,8，Alexander Scheer¹，Philippe Connes^2,3，Agnès Cibiel¹（Erytech Pharma；Laboratoire interuniversitaire de Biologie de la Motricité(LIBM)EA7424，Team?Vascular Biology and Red Blood Cell?，Université Claude Bernard Lyon 1，Université de Lyon；Labex GR-Ex；3P5 proteom’IC facility，Université de Paris，Institut Cochin，INSERM，CNRS；University of Colorado，Anschutz Medical Campus；Omix Technologies，Inc.；Inserm U1016，CNRS 8104，Université de Paris，Institut Cochin；Laboratoire de Biochimie et de Biologie Moléculaire，UF de biochimie des pathologies érythrocytaires，Centre de Biologie et de Pathologie Est，Hospices Civils de Lyon）.Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process[J].Acta Pharmaceutica Sinica B,2022,第4期 Jun Wang，Yanmei Hu，Madeleine Zheng（Department of Pharmacology and Toxicology，College of Pharmacy，the University of Arizona）.Enterovirus A71 antivirals：Past, present, and future[J].Acta Pharmaceutica Sinica B,2022,第4期 Chunlong Ma，Haozhou Tan，Juliana Choza，Yuyin Wang，Jun Wang（Department of Pharmacology and Toxicology，College of Pharmacy，the University of Arizona）.Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays[J].Acta Pharmaceutica Sinica B,2022,第4期 Jie Zhou¹，Wei Xu¹，Zezhong Liu¹，Chao Wang²，Shuai Xia¹，Qiaoshuai Lan¹，Yanxing Cai¹，Shan Su¹，Jing Pu¹，Lixiao Xing¹，Youhua Xie¹，Lu Lu¹，Shibo Jiang¹，Qian Wang¹（Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)，School of Basic Medical Sciences and BSL-3 Facility，Shanghai Institute of Infectious Diseases and Biosecurity，Fudan University；State Key Laboratory of Toxicology and Medical Countermeasures，Beijing Institute of Pharmacology and Toxicology）.A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhong Li^1,2，Jimin Xu³，Yuekun Lang²，Xiangmeng Wu¹，Saiyang Hu²，Subodh Kumar Samrat^1,2，Anil M.Tharappel^1,2，Lili Kuo²，David Butler⁴，Yongcheng Song⁵，Qing-Yu Zhang¹，Jia Zhou³，Hongmin Li^1,2（Department of Pharmacology and Toxicology，College of Pharmacy；Wadsworth Center，New York State Department of Health；Chemical Biology Program，Department of Pharmacology and Toxicology，University of Texas Medical Branch；The Neural Stem Cell Institute；Department of Pharmacology and Chemical Biology，Baylor College of Medicine）.In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus[J].Acta Pharmaceutica Sinica B,2022,第4期 Sameera Senaweera¹，Tiffany C.Edwards¹，Jayakanth Kankanala¹，Yan Wang^1,2，Rajkumar Lalji Sahani¹，Jiashu Xie¹，Robert J.Geraghty¹，Zhengqiang Wang¹（Center for Drug Design，College of Pharmacy，University of Minnesota；Translational Medicine R&D Center，Shenzhen Institutes of Advanced Technology，Chinese Academy of Sciences）.Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus（HCMV）[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiqiang Deng¹，Yu Dong¹，Xiaoting Zhou^2,3，Jia-Hong Lu¹，Zhenyu Yue²（State Key Laboratory of Quality Research in Chinese Medicine，Institute of Chinese Medical Sciences，University of Macau；Department of Neurology，the Friedman Brain Institute，Icahn School of Medicine at Mount Sinai；Department of Geriatrics，Xiangya Hospital，Central South University）.Pharmacological modulation of autophagy for Alzheimer’s disease therapy：Opportunities and obstacles[J].Acta Pharmaceutica Sinica B,2022,第4期 Yunlong Shan¹，Qi Ni¹，Qixiang Zhang¹，Mengying Zhang¹，Bin Wei²，Lingge Cheng¹，Chongjin Zhong¹，Xinyu Wang¹，Qingqing Wang¹，Jiali Liu¹，Jingwei Zhang¹，Jingjing Wu²，Guangji Wang¹，Fang Zhou¹（Key Laboratory of Drug Metabolism and Pharmacokinetics，State Key Laboratory of Natural Medicines，China Pharmaceutical University；Department of Hematology and Oncology，the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University）.Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiwei Zhang^1,2，Suling Ding¹，Zhe Wang³，Xiaowei Zhu¹，Zheliang Zhou¹，Weiwei Zhang¹，Xiangdong Yang^1,3,4,5，Junbo Ge^1,3,4,5（Institutes of Biomedical Sciences and Shanghai Institute of Cardiovascular Diseases，Zhongshan Hospital，Fudan University；Reproductive Medicine Centre，Zhongshan Hospital，Fudan University；Department of Cardiology，Zhongshan Hospital，Fudan University；NHC Key Laboratory of Viral Heart Diseases，Fudan University；Key Laboratory of Viral Heart Diseases，Chinese Academy of Medical Sciences）.Prmt1 upregulated by Hdc deficiency aggravates acute myocardial infarction via NETosis[J].Acta Pharmaceutica Sinica B,2022,第4期 Rong Xiang¹，Zhengsen Yu¹，Yang Wang¹，Lili Wang²，Shanshan Huo¹，Yanbai Li¹，Ruiying Liang¹，Qinghong Hao¹，Tianlei Ying³，Yaning Gao⁴，Fei Yu¹，Shibo Jiang³（College of Life Sciences，Hebei Agricultural University；Research Center of Chinese Jujube，Hebei Agricultural University；Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)，School of Basic Medical Sciences，Shanghai Institute of Infectious Diseases and Biosecurity，Fudan University；Beijing Pharma and Biotech Center）.Recent advances in developing small-molecule inhibitors against SARS-CoV-2[J].Acta Pharmaceutica Sinica B,2022,第4期 Saba R.Aliyari¹，Amir Ali Ghaffari¹，Olivier Pernet^1,2，Kislay Parvatiyar¹，Yao Wang¹，Hoda Gerami¹，Ann-Jay Tong¹，Laurent Vergnes³，Armin Takallou¹，Adel Zhang¹，Xiaochao Wei⁴，Linda D.Chilin⁵，Yuntao Wu⁵，Clay F.Semenkovich^4,6，Karen Reue³，Stephen T.Smale¹，Benhur Lee¹，Genhong Cheng¹（Department of Microbiology，Immunology and Molecular Genetics，University of California；En Viro International Laboratories；Department of Human Genetics，David Geffen School of Medicine，University of California；Division of Endocrinology，Metabolism and Lipid Research，Washington University School of Medicine；Center for Infectious Disease Research，School of Systems Biology，George Mason University Manassas；Diabetic Cardiovascular Disease Center，Washington，University School of Medicine）.Suppressing fatty acid synthase by type Ⅰ interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiwei Xiao^1,2，Huiyi Wei¹，Yi Xu³，Ahmed Haider²，Junjie Wei¹，Shiyu Yuan¹，Jian Rong²，Chunyu Zhao²，Guocong Li¹，Weibin Zhang⁴，Huangcan Chen⁴，Yuefeng Li⁵，Lingling Zhang¹，Jiyun Sun^1,2，Shaojuan Zhang¹，Hai-Bin Luo⁶，Sen Yan⁷，Qijun Cai¹，Lu Hou¹，Chao Che⁴，Steven H.Liang²，Lu Wang¹（Center of Cyclotron and PET Radiopharmaceuticals，Department of Nuclear Medicine and PET/CT-MRI Center，the First Affiliated Hospital of Jinan University；Division of Nuclear Medicine and Molecular Imaging，Massachusetts General Hospital&Department of Radiology，Harvard Medical School；Department of Cardiology，the First Affiliated Hospital of Jinan University；State Key Laboratory of Chemical Oncogenomics，Key Laboratory of Chemical Genomics，Peking University Shenzhen Graduate School；Guangdong Landau Biotechnology Co.Ltd.；Key Laboratory of Tropical Biological Resources of Ministry of Education，School of Pharmaceutical Sciences，Hainan University；Guangdong-Hongkong-Macau Institute of CNS Regeneration，Ministry of Education CNS Regeneration Collaborative Joint Laboratory，Jinan University）.Discovery of a highly specific ¹⁸F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofiuorination[J].Acta Pharmaceutica Sinica B,2022,第4期 Wen-Xing Ding¹，Russell H.Swerdlow²（Department of Pharmacology，Toxicology and Therapeutics，Department of Internal Medicine，the University of Kansas Medical Center；Department of Neurology，the University of Kansas Medical Center）.Editorial of special column on Drug targets and drug development for Alzheimer’s disease[J].Acta Pharmaceutica Sinica B,2022,第4期 Hongxi Hu，Xiaotong Lu，Huiyan Xu，Liyun Zhou（Pharmcube（Beijing）Co.，Ltd.）.Analysis of new drug registration and review in China in 2021[J].Acta Pharmaceutica Sinica B,2022,第4期 Jun Wang¹，Hongmin Li²（Department of Medicinal Chemistry，Ernest Mario School of Pharmacy，Rutgers，the State University of New Jersey；Department of Pharmacology and Toxicology，College of Pharmacy，University of Arizona）.Editorial of Special Column on Antiviral Drug Discovery and Pharmacology[J].Acta Pharmaceutica Sinica B,2022,第4期 Zhiwei Xiao，Huiyi Wei，Yi Xu，Ahmed Haider，Junjie Wei，Shiyu Yuan，Jian Rong，Chunyu Zhao，Guocong Li，Weibin Zhang，Huangcan Chen，Yuefeng Li，Lingling Zhang，Jiyun Sun，Shaojuan Zhang，Hai-Bin Luo（Center of Cyclotron and PET Radiopharmaceuticals,Department of Nuclear Medicine and PET/CT-MRI Center,the First Affiliated Hospital of Jinan University,Guangzhou 510630,China；Division of Nuclear Medicine and Molecular Imaging,Massachusetts Gener）.Discovery of a highly specific ^(18)F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination[J].药学学报（英文版),2022,第4期 Songtao Dong¹，Xiangnan Guo¹，Fei Han²，Zhonggui He¹，Yongjun Wang¹（Department of Pharmaceutics，Wuya College of Innovation，Shenyang Pharmaceutical University；School of Pharmacy，Shenyang Pharmaceutical University）.Emerging role of natural products in cancer immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第3期 Zhiwei Fan^1,2，Changyue Wu^2,3，Miaomiao Chen²，Yongying Jiang⁴，Yuanyuan Wu²，Renfang Mao⁴，Yihui Fan^1,2（Department of Pathogenic Biology，School of Medicine，Nantong University；Laboratory of Medical Science，School of Medicine，Nantong University；Department of Dermatology，Affiliated Hospital of Nantong University，Nantong University；Department of Pathophysiology，School of Medicine，Nantong University）.The generation of PD-L1 and PD-L2 in cancer cells：From nuclear chromatin reorganization to extracellular presentation[J].Acta Pharmaceutica Sinica B,2022,第3期 Cancan Zheng¹，Xiaomei Yu¹，Yiyao Liang²，Yidong Zhu³，Yan He³，Long Liao¹，Dingkang Wang¹，Yanming Yang¹，Xingfeng Yin¹，Ang Li²，Qingyu He¹，Bin Li¹（MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes，Institute of Life and Health Engineering，Jinan University；Guangdong Key Laboratory of Non-human Primate Research，Guangdong-Hong Kong-Macau Institute of CNS Regeneration，Key Laboratory of CNS Regeneration，Ministry of Education，Jinan University；MOE Key Laboratory of Tumor Molecular Biology and Guangdong Provincial Key Laboratory of Bioengineering Medicine，National Engineering Research Center of Genetic Medicine，Institute of Biomedicine，College of Life Science and Technology，Jinan University）.Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner[J].Acta Pharmaceutica Sinica B,2022,第3期 Geni Ye^1,2，Maohua Huang^1,2,3，Yong Li^1,2，Jie Ouyang^1,2，Minfeng Chen^1,2，Qing Wen^1,2，Xiaobo Li^1,2，Huhu Zeng^1,2，Pei Long^1,2，Zepei Fan⁴，Junqiang Yin⁴，Wencai Ye^1,2，Dongmei Zhang^1,2（College of Pharmacy，Jinan University；Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research，Jinan University；Integrated Chinese and Western Medicine Postdoctoral Research Station，Jinan University；Department of Musculoskeletal Oncology，the First Affiliated Hospital of Sun Yat-sen University）.The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway[J].Acta Pharmaceutica Sinica B,2022,第3期 Yingzi He^1,2，Zhiwei Zheng^1,2，Chang Liu^1,2，Wen Li^1,2，Liping Zhao^1,2，Guohui Nie³，Huawei Li^1,2,4,5（ENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital，State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science，Fudan University；NHC Key Laboratory of Hearing Medicine (Fudan University)；Department of Otolaryngology and Institute of Translational Medicine，Shenzhen Second People's Hospital/the First Affiliated Hospital of Shenzhen University Health Science Center；Institutes of Biomedical Sciences，Fudan University；The Institutes of Brain Science and the Collaborative Innovation Center for Brain Science，Fudan University）.Inhibiting DNA methylation alleviates cisplatininduced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1-PI3K/AKT pathway[J].Acta Pharmaceutica Sinica B,2022,第3期 Fangfang Wang^1,2，Sora Jin³，Franklin Mayca Pozo³，Danmei Tian^1,2，Xiyang Tang^1,2，Yi Dai^1,2，Xinsheng Yao^1,2，Jinshan Tang^1,2，Youwei Zhang³（Institute of Traditional Chinese Medicine and Natural Products，College of Pharmacy，Jinan University；Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drug Research，Jinan University；Department of Pharmacology，Case Comprehensive Cancer Center，Case Western Reserve University School of Medicine）.Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR[J].Acta Pharmaceutica Sinica B,2022,第3期 Wei Zhang^1,,3；Chengchao Xu^1,,4；Jichao Sun¹；Han-Ming Shen⁵；Jigang Wang^1,,4,6；Chuanbin Yang¹（Department of Geriatrics, Shenzhen People’s Hospital (the Second Clinical Medical College, Jinan University；the First Affiliated Hospital, Southern University of Science and Technology)；Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University；Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences；Faculty of Health Sciences, University of Macau；Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University）.Impairment of the autophagy-lysosomal pathway in Alzheimer’s diseases：Pathogenic mechanisms and therapeutic potential[J].Acta Pharmaceutica Sinica B,2022,第3期 Xu Zhang^1,2，Yuxiang Wang¹，Linghua Meng^1,2（Division of Anti-tumor Pharmacology，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences）.Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma：New opportunities towards molecularly targeted therapy[J].Acta Pharmaceutica Sinica B,2022,第3期首页上一页 6 7 8 9 10 下一页尾页共有12页，转到页

期刊文章列表